ered when PAPP-A is assessed as a biomarker in acute coronary syndromes.
Pregnancy-associated plasma protein A (PAPP-A) 3 is produced in unstable but not in stable coronary artery plaques (1 ) . Its production is increased in vulnerable and ruptured plaques of carotid arteries, and it is also found in plasma of these patients (2 ) . Serum PAPP-A concentrations are increased early in acute STelevation myocardial infarction (STEMI), and PAPP-A has been suggested as a useful diagnostic and prognostic tool in STEMI (3) (4) (5) . After coronary-reperfusion therapy for STEMI, plasma concentrations of PAPP-A increase more after percutaneous angioplasty (PCI) than after thrombolysis (6 ) . Results of a recent study based on the analysis of 2 historical cohorts of myocardial infarctions and experiments with mice suggest that intravenous administration of unfractionated heparin (UFH) increases plasma concentrations of PAPP-A (7 ). In acute coronary syndromes, the increase in the plasma PAPP-A concentration is due to the increase of noncomplexed, free PAPP-A, whereas PAPP-A typically circulates as a complex with the proform of eosinophil major basic protein (8 ) . PAPP-A concentrations are often increased in asymptomatic patients with chronic kidney disease, and high PAPP-A concentrations in these patients are associated with increased mortality (9, 10 ) . In end-stage renal disease, PAPP-A increases during a hemodialysis session via an unknown mechanism (11 ) .
To clarify the effect of heparin administration on serum PAPP-A concentrations, we studied 14 hemodialysis patients [mean (SD) age, 65 (15) years] during their dialysis sessions and studied 10 patients [mean age, 62 (9) years] who were undergoing elective coronary angiography.
Enoxaparin (dose, 40 -60 mg), a low molecular weight heparin (LMWH), was administered intravenously in the dialysis lines at the start of the dialysis of 10 dialysis patients. A heparin-free technique was used in 4 patients who had an increased risk of bleeding (12 ) . None of the 4 hemodialysis patients in the heparin-free protocol received LMWH at the start of dialysis, but 2 received a bolus of 20 mg enoxaparin intravenously 2 h after the start of dialysis to prevent clotting of the dialysis filter. For the coronary angiography patients, a 5000-IU bolus of UFH was given intravenously at the start of the procedure. One patient was treated with PCI and received 2 additional UFH boluses.
To analyze serum PAPP-A, we collected 2 mL venous blood from the arterial dialysis lines into siliconecoated Venoject evacuated blood-collection tubes with clot activator and an inert gel barrier (Terumo Europe). The blood samples were collected immediately before the dialysis session and at 5, 15, and 120 min after the start of the session. Sera were separated by centrifugation and stored in aliquots at Ϫ70°C until analysis. Additional samples were collected from the 2 dialysis patients who underwent heparin-free dialysis and then received a reduced LMWH bolus after 2 h of dialysis: at 5 min (both patients) and at 115 min (1 patient) after the first LMWH bolus. In the patients undergoing coronary angiography, blood samples were taken from the arterial sheath just before intravenous administration of UFH and at 5 min and 15 min after the start of the procedure. We also collected samples at 35 min and 110 min from a coronary angiography patient who underwent PCI and therefore received 2 extra heparin boluses. The study was approved by the local ethics committee and was conducted in accordance with the Declaration of Helsinki as revised in 1996; all blood samples were collected after informed written consent was obtained from the patients.
The serum concentrations of total and free PAPP-A were measured as previously described (13 ) . In brief, total PAPP-A and complexed PAPP-A were assayed in an Aio Immunoanalyzer (Innotrac Diagnostics) with premade dry-reagent wells containing the capture antibody and the europium chelate-labeled detection antibody. The total PAPP-A assay detects PAPP-A whether or not it is complexed with the proform of the eosinophil major basic protein, whereas the assay for complexed PAPP-A detects only the PAPP-A occurring as this complex. The concentration of free PAPP-A is calculated as the difference between the results for the total PAPP-A and complexed PAPP-A assays. The analytical and functional detection limits (imprecision Ͻ20%) were 0.18 mIU/L and 0.27 mIU/L, respectively, for the total PAPP-A assay and 0.23 mIU/L and 0.70 mIU/L for the complexed PAPP-A assay (13 ) . We previously reported the upper reference limits (97.5th percentile) for an apparently healthy population as 4.9 mIU/L for total PAPP-A and 1.3 mIU/L for free PAPP-A (13 ) .
To test the effect of LMWH and UFH on blood in vitro, we obtained blood samples from 5 patients immediately before dialysis and anticoagulated the samples with EDTA, hirudin, or citrate. Enoxaparin and UFH were added to the samples at concentrations approximating those of treated patients (LMWH, 8.5 g/L; UFH 1100 IU/L). The samples were incubated at room temperature for 30 min before the plasma was separated by centrifugation and analyzed.
Statistical analyses were performed with GraphPad Prism for Windows version 4.02 (GraphPad Software). Mann-Whitney U-tests and Wilcoxon signed rank tests with 2-tailed probabilities were used. Continuous variables are presented as the median (25th-75th percentiles). Table 1 presents the total and free PAPP-A concentrations in serum. Total and free PAPP-A concentrations were increased in the hemodialysis patients at the start of dialysis, compared with the typical values we had previously reported. The basal total PAPP-A concentration exceeded the upper reference limit in 10 of 14 patients, and the free PAPP-A concentration exceeded the upper reference limit in 13 of 14 patients. Eight of the patients had no history of cardiovascular disease. At the beginning of the hemodialysis session, rapid increases in total PAPP-A and free PAPP-A were detected within 5 min of administration of the anticoagulant in all patients (Table 1) . After this release, the concentrations decreased quickly. The increases in total and free PAPP-A were not related to age, sex, or history of cardiovascular disease and were seen both in patients with native-vein fistula and in patients with a central venous catheter. Heparin-free dialysis did not produce a statistically significant increase in PAPP-A concentrations (Table 1) ; however, when we gave a reduced LMWH dose to 2 patients at 2 h to prevent coagulation of the dialysis system during heparin-free dialysis, we observed immediate and rapid increases in total and free PAPP-A concentrations (results not shown).
In vitro addition of LMWH or UFH to samples of whole blood from dialysis patients anticoagulated with EDTA, citrate, or hirudin caused no changes in PAPP-A concentrations. We also studied plasma samples taken from the same patients in heparinanticoagulated phlebotomy tubes. The PAPP-A concentrations measured in these samples were not higher than those in samples collected in tubes with other anticoagulants or in serum samples. Thus, it is unlikely that the detected increases in PAPP-A are due to an analytical artifact. Tests of serial dilutions of 4 samples with a high PAPP-A response indicated that the measured PAPP-A concentration decreased linearly with dilution, supporting the specificity of our PAPP-A test.
At baseline, total and free PAPP-A concentrations were lower in coronary angiography patients than in dialysis patients (P Ͻ 0.001, Table 1 ). One of the angiography patients had no angiographically detectable coronary artery disease. None of the angiography patients had a total PAPP-A concentration above the upper reference limit at baseline, and the upper reference limit for free PAPP-A was exceeded in only 2 of 10 patients before angiography. A single UFH bolus caused a comparable rapid PAPP-A response during coronary angiography in all patients. The increase in total and free PAPP-A was smaller in angiography patients than in dialysis patients (P Ͻ 0.0001). The effect of repeated UFH boluses was evidenced in the patient who was treated with PCI.
The mechanism responsible for our results is unknown but is suggested by findings of recent studies. PAPP-A is known to bind heparin, and heparin competes with PAPP-A for binding to cell surfaces in vitro (14, 15 ) . This phenomenon may explain our observations. Similar to our results, administration of heparin in vivo has been shown to increase plasma concentrations of myeloperoxidase and lipoprotein lipase by liberating these enzymes from the vascular wall (16, 17 ) . The tissue origin of the heparin-induced increase of free PAPP-A in the serum is unknown. In addition to vascular endothelium, PAPP-A is found in ovaries, testes, colon, liver, kidney, and bone and is produced by several cell types (18 ) . Because the response occurs within minutes of heparin administration, PAPP-A release must originate from tissues with effective blood circulation, possibly the vasculature. The PAPP-A response was lower and slower in coronary angiography patients than in hemodialysis patients. It is possible that this difference is due to differences in administration, i.e., intravenous LMWH in the hemodialysis apparatus and intravenous UFH in angiography. Further studies involving, for example, blood samples from the coronary sinus and crossover of dialysis patients to UFH and of angiography patients to LMWH might provide valuable information. In acute coronary syndromes, LMWH is usually administered subcutaneously. Whether subcutaneous LMWH increases PAPP-A concentrations in the circulation remains to be studied, and whether the extent of heparin-induced PAPP-A release correlates with the atherosclerotic lesions of the vasculature also should be investigated.
Our results show that intravenously administered UFH and LMWH cause a rapid and intense increase in serum PAPP-A concentrations. This effect was seen both during coronary angiography and during hemodialysis. From our observations, it is obvious that the use of PAPP-A as a prognostic and diagnostic biomarker of acute coronary syndromes must be reevaluated, because heparins are a mainstay of their therapy. Heparin-induced changes in PAPP-A concentration might explain some of the controversies of previous studies of patients with STEMI and the apparent fluctuation in their PAPP-A concentrations (19 ) . Our findings do not rule out PAPP-A measurement in this setting but do indicate that blood samples should not be collected during heparin treatment. We recommend that this effect be taken into account when PAPP-A is studied as a biomarker in acute coronary syndromes.
